Abstract:Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others. Psychedelics belong to a more general class of compounds known as psychoplastogens, which robustly promote structural and functional neural plasticity in key circuits relevant to brain health. Here we discuss the importance of structural plasticity in the treatment of neuropsychiatric diseases, as well as the evidence demonstrating that psychedelics are among the most effective chemical modulators of neural plasticity studied to date. Furthermore, we provide a theoretical framework with the potential to explain why psychedelic compounds produce long-lasting therapeutic effects across a wide range of brain disorders. Despite their promise as broadly efficacious neurotherapeutics, there are several issues associated with psychedelic-based medicines that drastically limit their clinical scalability. We discuss these challenges and how they might be overcome through the development of non-hallucinogenic psychoplastogens. The clinical use of psychedelics and other psychoplastogenic compounds marks a paradigm shift in neuropsychiatry toward therapeutic approaches relying on the selective modulation of neural circuits with small molecule drugs. Psychoplastogen research brings us one step closer to actually curing mental illness by rectifying the underlying pathophysiology of disorders like depression, moving beyond simply treating disease symptoms. However, determining how to most effectively deploy psychoplastogenic medicines at scale will be an important consideration as the field moves forward.

What is needed for the roll-out of psychedelic treatments?

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Psychedelic research at a crossroads

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Exploring the regulatory framework of psychedelics in the US & Europe

Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?

Developing an Ethics and Policy Framework for Psychedelic Clinical Care

Practical considerations in the establishment of psychedelic research programs

Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics

A regulatory framework review of Schedule I psychedelics in the United States

Psychedelics and Other Psychoplastogens for Treating Mental Illness

The cyclical revival of psychedelics in psychiatric treatment

Psychedelics and Neural Plasticity: Therapeutic Implications

Psychedelics and the treatment of eating disorders: considerations for future research and practice

The economics of psychedelic-assisted therapies: A research agenda

The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Expert recommendations for Germany's integration of psychedelic-assisted therapy

Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials

Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview